Main Component Analysis and Cluster Analysis on Comprehensive Quality of Adverse Drug Reaction Reports

Abstract

Abstract: Objective To discuss the thought and method about the establishment of qualifying ADR reports from the ADR units. Methods By the main component analysis and cluster analysis to simplify data, the key index was selected to assess the quality of ADR reports provided by National Adverse Drug Reaction Monitoring System of Jiangxi Province in 2013. Results The ADR reports of D group from Ji'an city was with the highest quality in all four groups divided by cluster analysis. Conclusion The main component analysis and cluster analysis can be used to qualify the ADR reports from each city by compositive score.

Key words: drug adverse reaction, report quality, the main component analysis, cluster analysis, comprehensive evaluation

CLC Number:

R994.11
R95

XU Jin，LI Xin-ling，ZHOU Juan. Main Component Analysis and Cluster Analysis on Comprehensive Quality of Adverse Drug Reaction Reports[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 92-95.

[1]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[2]	ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling. Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
[3]	YANG Le, XIA Dongsheng, WANG Tao. Risks to safety of vitamin B₆ injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
[4]	YUE Xiaolin, LU Song, ZHANG Lan. Research in the construction of comprehensive evaluation systems of drugs in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
[5]	JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin. Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
[6]	WANG Yadan, YAN Jiangong, CHEN Minghui, PANG Yu, DAI Zhong, MA Shuangcheng. UPLC fingerprints of tripterygium glycosides tablets from different manufacturers [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 146-151.
[7]	WU Na, SU Dan, WANG Haikun, SHEN Aizong. Quality evaluation of adverse drug reaction reports in oncology department based on weighted Topsis-rank-sum ratio method [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 101-105.
[8]	YANG Ping, LU Song, DONG Xianzhe, ZHANG Lan. Research progress in comprehensive evaluation methods of drugs [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 803-806.
[9]	WEI Ruili, ZHAO Xiaoxiao, XI Junyu, XIE Yanming. Regularity of combined medication of elemene emulsion injection in the treatment of malignant tumors in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1206-1212.
[10]	CAI Jun, LI Huixin, LIU Mengying, YAO Yao, GE Weihong. Safe Use of Lopinavir/Ritonavir for COVID-19 Based on Literature Analysis of Adverse Reactions [J]. Chinese Journal of Pharmacovigilance, 2020, 17(6): 326-331.
[11]	SANG Yuan, WU Shifu, LU Changfei, XIE Yanjun, CUI Xiaokang, XU Lili, LIU Wenwen, HUO Yanfei. Problems and Thoughts on Reporting and Monitoring of Adverse Drug Reactions in Drug Manufacturers [J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.
[12]	BAN Bing-kun, WEI Jing-tu, LI Er-ping, ZHOU Li, SUN Rong. Status Analysis of the Adverse Drug Reaction Monitoring Work Basing on the Quantity and Quality of ADR Reports [J]. Chinese Journal of Pharmacovigilance, 2016, 13(6): 344-346.
[13]	SHI Wen-hui, CHEN Ying, YAO Jie, SUN Zhi-ming, XU Hao-qin. Study on Drospirenone and Ethinylestradiol Tablets Using FDA Public Data Program [J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 552-555.
[14]	ZHANG Xue-mei, GUO Jia-dong, FENG Bian-ling*, YANG Shi-min. Study on the ADR Monitoring of Medical Institutions of 6 Provinces in China [J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 603-606.
[15]	ZHANG Gui-ju, CHU Xiao-yi, TIAN Yue-jie, HUANG Lin, LI Yu-ji. Implication of EU Pharmacovigilance System to China [J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 593-596.

Main Component Analysis and Cluster Analysis on Comprehensive Quality of Adverse Drug Reaction Reports

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics